U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07651085) titled 'Biomarkers in Alzheimer's and Parkinson's Diseases for IA' on July 29, 2024.
Brief Summary: Investigate whether endogenous and exogenous risk factors, the presence of pathological amyloid aggregates and alpha-synuclein in the CSF, brain connectivity, and some clinical and biological indices such as vigilance, general motility, the sleep-wake cycle, genomic instability and possible DNA damage may correlate with (or predict) the clinical condition of mild cognitive impairment (MCI) and dementia in patients with Alzheimer's disease (AD) and Parkinson's disease (PD).
Study Start Date: Feb. 08, 2024
Study Type: OBSERVATIONAL
Condition...